Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
tyrosine kinase inhibitors	4190	941678-49-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ruxolitinib jakafi INCB 018424 ruxolitinib phosphate jakavi	a kinase inhibitor, inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Although some small studies have suggested possibility of benefit from ruxolitinib in patients with COVID-19, it is not recommended the use of JAK inhibitors other than baricitinib for the treatment of COVID-19. Molecular weight: 306.37 Formula: C17H18N6 CLOGP: 2.29 LIPINSKI: 0 HAC: 6 HDO: 1 TPSA: 83.18 ALOGS: -3.42 ROTB: 4 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ruxolitinib
jakafi
INCB 018424
ruxolitinib phosphate
jakavi

a kinase inhibitor, inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Although some small studies have suggested possibility of benefit from ruxolitinib in patients with COVID-19, it is not recommended the use of JAK inhibitors other than baricitinib for the treatment of COVID-19.

Molecular weight: 306.37
Formula: C17H18N6
CLOGP: 2.29
LIPINSKI: 0
HAC: 6
HDO: 1
TPSA: 83.18
ALOGS: -3.42
ROTB: 4

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O

ADMET properties:

Property	Value	Reference
fu (Fraction unbound in plasma)	0.08 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	2.769		High	0.81
caco2-efflux	Caco-2 efflux ratio (BA/AB)	1.040		High	0.81
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	78.886	10^-6 cm/s	High	0.81
dh-clint	Dog hepatocyte intrinsic clearance	11.912	uL/min/10^6 cells	High	0.81
dppb	Dog plasma protein binding (% unbound)	20.940	%	High	0.81
fcs-ppb	Fetal calf serum protein binding (% unbound)	38.200	%	High	0.81
herg	hERG pIC50	4.619	pIC50	High	0.81
hh-clint	Human hepatocyte intrinsic clearance	4.560	uL/min/10^6 cells	High	0.81
hlm-clint	Human liver microsomal intrinsic clearance	29.376	uL/min/mg protein	High	0.81
hppb	Human plasma protein binding (% unbound)	12.730	%	High	0.81
kinase-safety-class	AAK1,ABL2,ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BLK,BMX,BRAF,CAMK2A,CAMK2B,CAMK2D,CAMK2G,CDK1,CDK14,CDK16,CDK19,CDK2,CDK3,CDK4,CDK5,CDK6,CDK7,CDK8,CDK9,CHEK1,CHEK2,CLK1,CLK2,CLK4,CSF1R,CSNK1A1,CSNK1G2,CSNK1G3,CSNK2A3,DDR1,DYRK1A,DYRK1B,DYRK2,DYRK3,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,FGFR1,FLT3,FYN,GAK,GRK1,GRK2,GRK3,GSK3A,GSK3B,HASPIN,IGF1R,IKBKB,INSR,IRAK1,IRAK3,IRAK4,ITK,JAK1,JAK2,JAK3,KDR,KIT,LCK,LRRK2,LYN,MAP2K1,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K19,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP3K9,MAP4K1,MAP4K2,MAP4K3,MAP4K5,MAPK1,MAPK10,MAPK15,MAPK3,MAPK7,MAPK9,MARK1,MARK2,MARK3,MARK4,MELK,MET,MINK1,MKNK1,MKNK2,MTOR,NTRK1,NTRK2,NTRK3,NUAK1,PAK4,PDGFRB,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CD,PIK3CG,PIM1,PIM2,PIM3,PRKAA1,PRKAA2,PRKACA,PRKCA,PRKCD,PRKCZ,PRKD1,PRKDC,PRKG1,RET,RIPK1,RIPK3,ROCK1,ROCK2,RPS6KA1,SGK1,SIK2,SIK3,SRC,STK16,STK17A,STK3,STK33,STK4,SYK,TEK,TGFBR1,TNIK,TTK,TYRO3,ULK1,ULK2,YES1	158
kinase-selectivity-class	AAK1,ACVR2B,AKT1,AURKA,AURKB,AURKC,AXL,BRAF,CAMK2B,CAMK2D,CDK1,CDK2,CDK9,CHEK1,CLK2,CLK4,DYRK1A,DYRK1B,DYRK2,EGFR,FGFR1,FLT3,GRK2,GSK3B,HASPIN,IRAK1,IRAK3,JAK1,JAK2,JAK3,KDR,LCK,LRRK2,MAP2K1,MAP3K10,MAP3K11,MAP3K2,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAP4K5,MAPK1,MAPK7,MARK3,MARK4,MELK,MET,MKNK2,NTRK1,NTRK3,NUAK1,PDK1,PRKAA1,PRKAA2,PRKACA,PRKCD,ROCK1,ROCK2,SGK1,SIK2,SIK3,STK17A,STK33,SYK,ULK1	66
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	1.462		High	1
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	2.588		High	0.81
mh-clint	Mouse hepatocyte intrinsic clearance	99.312		High	0.81
mppb	Mouse plasma protein binding (% unbound)	17.510		High	0.81
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	7.464		High	0.81
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	26.680	%	High	0.81
rat-kpuu-brain	Rat brain Kpuu	0.079	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	66.834	uL/min/10^6 cells	High	0.81
rh-fuinc	Rat hepatocyte fraction unbound in incubation	68.130	%	High	0.81
rppb	Rat plasma protein binding (% unbound)	14.690	%	High	0.81
solubility-dd	Solubility at pH 7.4 in DMSO	111.944	uM	High	0.81

Approvals:

Date	Agency	Company
Nov. 16, 2011	FDA	INCYTE CORP
Aug. 23, 2012	EMA	NOVARTIS EUROPHARM LIMITED
July 4, 2014	PMDA	Novartis Pharma K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Splenomegaly	453.04	17.32	160	24785	12764	90590738
Platelet count decreased	418.81	17.32	327	24618	136642	90466860
Platelet count increased	415.66	17.32	171	24774	20688	90582814
Haemoglobin decreased	382.89	17.32	333	24612	161623	90441879
Anaemia	244.09	17.32	385	24560	352417	90251085
Full blood count abnormal	192.61	17.32	122	24823	36475	90567027
Death	173.08	17.32	385	24560	456166	90147336
White blood cell count increased	168.21	17.32	143	24802	67098	90536404
Product dose omission issue	162.33	17.32	289	24656	291398	90312104
Dermatitis atopic	151.04	17.32	89	24856	23383	90580119
Graft versus host disease in gastrointestinal tract	148.68	17.32	53	24892	4335	90599167
Cytomegalovirus infection reactivation	135.40	17.32	58	24887	7742	90595760
Thrombotic microangiopathy	134.77	17.32	72	24873	15671	90587831
Graft versus host disease in liver	131.33	17.32	34	24911	929	90602573
Red blood cell count decreased	129.25	17.32	105	24840	46246	90557256
Graft versus host disease in skin	124.76	17.32	45	24900	3808	90599694
Thrombocytopenia	122.73	17.32	212	24733	208513	90394989
Acute myeloid leukaemia	116.62	17.32	72	24873	20568	90582934
Bronchopulmonary aspergillosis	102.85	17.32	54	24891	11344	90592158
Epstein-Barr virus infection reactivation	100.64	17.32	31	24914	1606	90601896
Bronchiolitis obliterans syndrome	99.36	17.32	23	24922	388	90603114
Chronic graft versus host disease	96.44	17.32	38	24907	4101	90599401
Febrile neutropenia	93.24	17.32	161	24784	158188	90445314
Graft versus host disease	92.26	17.32	45	24900	8099	90595403
Weight increased	87.37	17.32	283	24662	417644	90185858
Acute graft versus host disease	83.01	17.32	37	24908	5431	90598071
Myelofibrosis	81.02	17.32	26	24919	1541	90601961
Haemophagocytic lymphohistiocytosis	79.97	17.32	51	24894	15408	90588094
Increased appetite	79.34	17.32	46	24899	11719	90591783
Arthropathy	75.31	17.32	7	24938	366235	90237267
Interleukin level increased	72.44	17.32	20	24925	702	90602800
Contraindicated product administered	71.89	17.32	4	24941	320135	90283367
Platelet count abnormal	71.19	17.32	31	24914	4304	90599198
Product use in unapproved indication	69.58	17.32	227	24718	336009	90267493
Cytomegalovirus infection	69.41	17.32	58	24887	26544	90576958
Glossodynia	69.34	17.32	5	24940	321774	90281728
Flatulence	68.58	17.32	70	24875	41297	90562205
Haematocrit decreased	64.34	17.32	68	24877	41764	90561738
Drug hypersensitivity	63.72	17.32	24	24921	463585	90139917
Hypersensitivity	60.08	17.32	25	24920	454652	90148850
Contusion	59.70	17.32	178	24767	251038	90352464
Herpes simplex	58.74	17.32	36	24909	10145	90593357
Leukocytosis	57.96	17.32	56	24889	30934	90572568
Pulmonary mucormycosis	57.35	17.32	16	24929	584	90602918
Chronic graft versus host disease in eye	56.52	17.32	13	24932	213	90603289
Blood lactate dehydrogenase increased	56.47	17.32	51	24894	25881	90577621
Chronic graft versus host disease oral	55.90	17.32	13	24932	224	90603278
Wound	54.47	17.32	9	24936	302971	90300531
Aspergillus infection	54.23	17.32	35	24910	10788	90592714
Chronic graft versus host disease in skin	53.72	17.32	18	24927	1222	90602280
Musculoskeletal stiffness	52.88	17.32	9	24936	296523	90306979
Joint swelling	51.58	17.32	38	24907	503262	90100240
Therapeutic product effect decreased	50.44	17.32	8	24937	277563	90325939
Disease progression	50.26	17.32	124	24821	156491	90447011
Drug ineffective for unapproved indication	49.02	17.32	75	24870	66569	90536933
Exposure during pregnancy	47.82	17.32	5	24940	238405	90365097
Bone pain	45.94	17.32	70	24875	61913	90541589
Maternal exposure during pregnancy	45.64	17.32	21	24924	360042	90243460
Graft versus host disease in lung	45.04	17.32	13	24932	537	90602965
Viral haemorrhagic cystitis	43.01	17.32	16	24929	1477	90602025
Injury	42.68	17.32	3	24942	197346	90406156
BK virus infection	42.55	17.32	22	24923	4476	90599026
Sepsis	42.29	17.32	127	24818	179687	90423815
Lower respiratory tract infection	41.73	17.32	9	24936	250650	90352852
Haemorrhage	41.39	17.32	71	24874	69298	90534204
Cystitis haemorrhagic	41.05	17.32	23	24922	5490	90598012
Staphylococcal infection	40.65	17.32	58	24887	48381	90555121
Epistaxis	40.51	17.32	79	24866	85046	90518456
White blood cell count decreased	40.22	17.32	119	24826	166990	90436512
Dry skin	39.82	17.32	80	24865	87993	90515509
Ill-defined disorder	39.44	17.32	3	24942	184888	90418614
Swelling	38.73	17.32	35	24910	419023	90184479
Pancytopenia	38.34	17.32	95	24850	120168	90483334
Hepatic enzyme increased	37.24	17.32	27	24918	360709	90242793
Off label use	37.05	17.32	464	24481	1101788	89501714
Post transplant lymphoproliferative disorder	36.12	17.32	23	24922	6926	90596576
Hypogammaglobulinaemia	35.84	17.32	27	24918	10647	90592855
Transfusion	35.36	17.32	33	24912	17455	90586047
Osteoarthritis	34.75	17.32	6	24939	195724	90407778
Therapeutic response unexpected	34.41	17.32	36	24909	21844	90581658
Mobility decreased	34.38	17.32	13	24932	250721	90352781
Chemokine increased	34.17	17.32	6	24939	21	90603481
Urticaria	34.15	17.32	22	24923	312712	90290790
Venoocclusive liver disease	34.08	17.32	21	24924	5972	90597530
Citrobacter infection	33.69	17.32	11	24934	689	90602813
Adenovirus infection	33.65	17.32	19	24926	4603	90598899
Primary myelofibrosis	33.27	17.32	7	24938	74	90603428
Acute graft versus host disease in skin	33.14	17.32	19	24926	4737	90598765
Parvovirus infection	33.02	17.32	10	24935	489	90603013
Skin exfoliation	32.28	17.32	63	24882	67850	90535652
Cytomegalovirus viraemia	31.90	17.32	22	24923	7564	90595938
Mucosal inflammation	31.81	17.32	57	24888	57568	90545934
Dizziness	31.59	17.32	273	24672	589011	90014491
Wheezing	31.56	17.32	13	24932	238067	90365435
Fungal endocarditis	31.51	17.32	9	24936	358	90603144
Eczema	31.39	17.32	54	24891	52816	90550686
Splenectomy	30.80	17.32	10	24935	615	90602887
JC virus infection	30.72	17.32	15	24930	2704	90600798
Impaired healing	30.70	17.32	13	24932	234186	90369316
Urinary tract infection bacterial	30.69	17.32	20	24925	6265	90597237
Abdominal distension	30.47	17.32	92	24853	130509	90472993
Klebsiella infection	30.11	17.32	24	24921	10273	90593229
Infective aneurysm	29.94	17.32	9	24936	429	90603073
Cytopenia	29.78	17.32	30	24915	17419	90586083
Hyperuricaemia	29.47	17.32	20	24925	6699	90596803
Drug resistance	29.37	17.32	39	24906	30410	90573092
Enterovirus infection	29.05	17.32	12	24933	1462	90602040
Skin lesion	28.82	17.32	43	24902	37322	90566180
Haemorrhage urinary tract	28.66	17.32	11	24934	1106	90602396
Liver injury	28.64	17.32	6	24939	170561	90432941
Gastroenteritis adenovirus	28.44	17.32	8	24937	301	90603201
Blast cell count increased	28.26	17.32	9	24936	520	90602982
Bladder hypertrophy	28.16	17.32	9	24936	526	90602976
Clostridial sepsis	27.56	17.32	9	24936	564	90602938
Psoriasis	27.42	17.32	4	24941	147750	90455752
Pneumatosis intestinalis	27.40	17.32	15	24930	3422	90600080
Microangiopathy	27.30	17.32	12	24933	1703	90601799
Herpes zoster	27.29	17.32	72	24873	94572	90508930
Organising pneumonia	27.26	17.32	20	24925	7577	90595925
Respiratory failure	27.23	17.32	83	24862	118335	90485167
Leukaemia	27.14	17.32	17	24928	4975	90598527
Oral herpes	26.46	17.32	39	24906	33485	90570017
Myeloproliferative neoplasm	26.28	17.32	9	24936	653	90602849
Pain	26.17	17.32	164	24781	996177	89607325
Iron overload	25.96	17.32	10	24935	1015	90602487
Epstein-Barr virus infection	25.84	17.32	22	24923	10322	90593180
Second primary malignancy	25.78	17.32	22	24923	10356	90593146
Epstein-Barr viraemia	25.74	17.32	11	24934	1459	90602043
Pneumonia adenoviral	25.51	17.32	7	24938	240	90603262
Gastrointestinal disorder	25.46	17.32	20	24925	256667	90346835
Intentional product use issue	25.44	17.32	14	24931	216878	90386624
Small intestine gangrene	25.24	17.32	5	24940	38	90603464
Acute graft versus host disease in intestine	25.07	17.32	12	24933	2071	90601431
Spleen disorder	24.92	17.32	10	24935	1131	90602371
Cachexia	24.44	17.32	18	24927	6860	90596642
Viraemia	24.40	17.32	11	24934	1658	90601844
Rhinovirus infection	24.39	17.32	17	24928	5946	90597556
Eye infection bacterial	23.94	17.32	7	24938	303	90603199
Drug intolerance	23.94	17.32	55	24890	447536	90155966
Gout	23.46	17.32	26	24919	16833	90586669
Serum ferritin increased	23.31	17.32	18	24927	7363	90596139
Chronic graft versus host disease in liver	23.18	17.32	7	24938	339	90603163
Varicella zoster virus infection	23.11	17.32	14	24931	3863	90599639
Haemophilus infection	22.85	17.32	10	24935	1404	90602098
Confusional state	22.69	17.32	45	24900	386160	90217342
Symptom masked	22.48	17.32	9	24936	1012	90602490
Pulmonary haemorrhage	22	17.32	18	24927	7995	90595507
Overdose	21.90	17.32	8	24937	157701	90445801
Pneumonia fungal	21.88	17.32	17	24928	7014	90596488
Pruritus	21.66	17.32	236	24709	541289	90062213
Promyelocyte count increased	21.60	17.32	3	24942	0	90603502
Skin haemorrhage	21.57	17.32	28	24917	21352	90582150
Gastrointestinal haemorrhage	21.44	17.32	64	24881	90184	90513318
Asthma	21.44	17.32	21	24924	242139	90361363
Basophil count increased	21.44	17.32	9	24936	1142	90602360
Fatigue	21.32	17.32	440	24505	1153583	89449919
Type 2 diabetes mellitus	21.23	17.32	15	24930	203229	90400273
Toxicity to various agents	21.13	17.32	29	24916	287817	90315685
Multiple organ dysfunction syndrome	20.74	17.32	53	24892	68283	90535219
Clubbing	20.64	17.32	7	24938	493	90603009
Gastrooesophageal reflux disease	20.60	17.32	10	24935	166327	90437175
Encopresis	20.48	17.32	5	24940	107	90603395
Weaning failure	20.19	17.32	7	24938	527	90602975
Sinusitis	20.13	17.32	40	24905	343048	90260454
Babesiosis	20.10	17.32	6	24939	279	90603223
Blast cells present	19.96	17.32	7	24938	545	90602957
Basophil percentage increased	19.85	17.32	5	24940	122	90603380
Blood cholesterol increased	19.64	17.32	17	24928	207995	90395507
Cytomegalovirus colitis	19.60	17.32	12	24933	3374	90600128
Hypergammaglobulinaemia benign monoclonal	19.50	17.32	8	24937	958	90602544
Obesity	19.24	17.32	3	24942	105504	90497998
Chest pain	18.98	17.32	37	24908	319608	90283894
Red blood cell count increased	18.79	17.32	12	24933	3631	90599871
Loss of personal independence in daily activities	18.74	17.32	7	24938	136098	90467404
Enterococcal infection	18.57	17.32	18	24927	9973	90593529
Osteonecrosis	18.54	17.32	29	24916	26212	90577290
Sciatica	18.23	17.32	3	24942	101379	90502123
Lip dry	18.12	17.32	3	24942	100952	90502550
Product use issue	18.07	17.32	40	24905	329879	90273623
Acute leukaemia	17.86	17.32	8	24937	1188	90602314
Alpha haemolytic streptococcal infection	17.81	17.32	9	24936	1745	90601757
Eye infection toxoplasmal	17.78	17.32	6	24939	416	90603086
Hepatomegaly	17.60	17.32	20	24925	13306	90590196
Myocardial oedema	17.39	17.32	6	24939	445	90603057

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Splenomegaly	394.87	14.66	205	28968	16842	42575320
Platelet count decreased	273.56	14.66	401	28772	138180	42453982
Haemoglobin decreased	224.16	14.66	357	28816	132114	42460048
Adenovirus infection	187.20	14.66	92	29081	6717	42585445
Platelet count increased	184.73	14.66	106	29067	10597	42581565
Anaemia	178.30	14.66	506	28667	279772	42312390
Febrile neutropenia	177.80	14.66	392	28781	185311	42406851
Death	148.21	14.66	675	28498	470510	42121652
White blood cell count increased	134.46	14.66	160	29013	44927	42547235
Stenotrophomonas infection	132.43	14.66	60	29113	3644	42588518
Iron overload	125.16	14.66	45	29128	1490	42590672
Acute myeloid leukaemia	122.86	14.66	110	29063	22146	42570016
Graft versus host disease	111.76	14.66	83	29090	12842	42579320
Graft versus host disease in skin	110.16	14.66	59	29114	5153	42587009
Second primary malignancy	104.79	14.66	71	29102	9504	42582658
Cytomegalovirus infection reactivation	103.93	14.66	75	29098	11103	42581059
Graft versus host disease in gastrointestinal tract	102.51	14.66	56	29117	5087	42587075
Acute graft versus host disease	102.23	14.66	66	29107	8149	42584013
Myelofibrosis	89.22	14.66	37	29136	1810	42590352
Graft versus host disease in liver	79.73	14.66	33	29140	1606	42590556
Acute graft versus host disease in intestine	78.69	14.66	43	29130	3908	42588254
Full blood count abnormal	73.00	14.66	96	29077	29780	42562382
Red blood cell count decreased	69.16	14.66	98	29075	32617	42559545
Chronic graft versus host disease in skin	67.02	14.66	29	29144	1577	42590585
Product use in unapproved indication	66.50	14.66	276	28897	184180	42407982
Acute graft versus host disease in liver	64.61	14.66	30	29143	1928	42590234
Scleroderma	64.19	14.66	29	29144	1749	42590413
Thrombocytopenia	63.41	14.66	278	28895	190001	42402161
Bronchiolitis obliterans syndrome	62.09	14.66	18	29155	293	42591869
Enterovirus infection	59.42	14.66	25	29148	1268	42590894
Thrombotic microangiopathy	58.75	14.66	61	29112	14721	42577441
Drug interaction	58.46	14.66	58	29115	266941	42325221
BK virus infection	57.76	14.66	48	29125	8736	42583426
Drug ineffective for unapproved indication	56.44	14.66	108	29065	46055	42546107
Contusion	56.04	14.66	102	29071	41883	42550279
Polyomavirus-associated nephropathy	55.24	14.66	39	29134	5576	42586586
Blast cell count increased	54.75	14.66	23	29150	1162	42591000
Product dose omission issue	54.06	14.66	229	28944	154136	42438026
Acute graft versus host disease in skin	53.94	14.66	43	29130	7381	42584781
Completed suicide	53.82	14.66	3	29170	96462	42495700
Toxicity to various agents	53.41	14.66	47	29126	229089	42363073
Night sweats	53.22	14.66	67	29106	19902	42572260
Haemosiderosis	51.88	14.66	16	29157	325	42591837
Aspergillus infection	51.84	14.66	59	29114	15778	42576384
Necrotising retinitis	50.99	14.66	21	29152	1009	42591153
Acute leukaemia	50.59	14.66	22	29151	1211	42590951
Respiratory syncytial virus infection	48.94	14.66	40	29133	7112	42585050
Overdose	48.80	14.66	7	29166	105257	42486905
Enterococcal bacteraemia	47.57	14.66	27	29146	2640	42589522
Varicella zoster virus infection	45.50	14.66	26	29147	2575	42589587
Emphysematous cholecystitis	44.84	14.66	11	29162	90	42592072
Epistaxis	44.52	14.66	123	29050	66703	42525459
Graft versus host disease in lung	43.06	14.66	17	29156	731	42591431
Multiple organ dysfunction syndrome	42.91	14.66	155	29018	96880	42495282
Nocardiosis	41.91	14.66	32	29141	5158	42587004
Hypotension	41.86	14.66	70	29103	257561	42334601
Pneumonia	41.48	14.66	456	28717	421693	42170469
Cytomegalovirus infection	41.23	14.66	77	29096	32229	42559933
Rebound effect	39.77	14.66	36	29137	7343	42584819
Central nervous system viral infection	39.29	14.66	11	29162	157	42592005
Bradycardia	38.89	14.66	6	29167	85478	42506684
Haematocrit decreased	38.23	14.66	78	29095	34830	42557332
Chronic graft versus host disease	37.70	14.66	32	29141	5993	42586169
Therapy non-responder	37.32	14.66	100	29073	53259	42538903
Dermatitis atopic	36.90	14.66	44	29129	12360	42579802
Type III immune complex mediated reaction	36.23	14.66	14	29159	568	42591594
Respiratory tract inflammation	36.11	14.66	13	29160	432	42591730
MAGIC syndrome	35.51	14.66	8	29165	43	42592119
Rhinovirus infection	35.40	14.66	32	29141	6516	42585646
Parainfluenzae virus infection	35.13	14.66	25	29148	3618	42588544
Idiopathic pneumonia syndrome	34.86	14.66	13	29160	478	42591684
Leukaemia	34.78	14.66	30	29143	5742	42586420
Early satiety	33.98	14.66	15	29158	856	42591306
Herpes simplex pneumonia	33.67	14.66	11	29162	271	42591891
Alveolar proteinosis	33.16	14.66	14	29159	716	42591446
Disseminated mucormycosis	32.96	14.66	17	29156	1374	42590788
NPM1 gene mutation	32.92	14.66	9	29164	117	42592045
Immunosuppression	32.01	14.66	34	29139	8419	42583743
Eye infection fungal	31.34	14.66	12	29161	475	42591687
Pyrexia	30.92	14.66	408	28765	393634	42198528
Pneumoretroperitoneum	30.85	14.66	9	29164	150	42592012
Platelet count abnormal	30.57	14.66	23	29150	3626	42588536
Chimerism	30.54	14.66	10	29163	248	42591914
Chronic graft versus host disease oral	29.61	14.66	11	29162	400	42591762
Cytopenia	29.26	14.66	47	29126	17450	42574712
Pneumatosis intestinalis	29.25	14.66	25	29148	4727	42587435
Transfusion	29.17	14.66	36	29137	10478	42581684
Squamous cell carcinoma	29.08	14.66	40	29133	12942	42579220
Blast cell crisis	28.58	14.66	8	29165	114	42592048
Ejection fraction abnormal	28.32	14.66	15	29158	1280	42590882
Bacterial sepsis	28.03	14.66	28	29145	6454	42585708
Enterocolitis viral	28.02	14.66	11	29162	466	42591696
Urethral polyp	27.94	14.66	7	29166	63	42592099
Herpes simplex	27.69	14.66	29	29144	7066	42585096
Epstein-Barr viraemia	27.52	14.66	18	29155	2271	42589891
Syncope	27.51	14.66	17	29156	99389	42492773
Leukocytosis	27.48	14.66	62	29111	29646	42562516
Thyroid gland abscess	27.10	14.66	7	29166	72	42592090
Acute myeloid leukaemia recurrent	26.93	14.66	21	29152	3491	42588671
Off label use	26.73	14.66	597	28576	637738	41954424
Rhabdomyolysis	26.68	14.66	10	29163	78009	42514153
White blood cell count decreased	26.48	14.66	147	29026	110249	42481913
Optic neuropathy	26.00	14.66	18	29155	2494	42589668
Confusional state	25.86	14.66	47	29126	167550	42424612
Myeloproliferative neoplasm	25.64	14.66	12	29161	785	42591377
Pseudomonas infection	25.57	14.66	42	29131	15881	42576281
Chronic graft versus host disease in eye	25.53	14.66	9	29164	281	42591881
Fatigue	25.53	14.66	429	28744	435212	42156950
Cerebral artery embolism	25.33	14.66	13	29160	1040	42591122
Splenectomy	25.26	14.66	10	29163	433	42591729
Cystitis haemorrhagic	25.17	14.66	28	29145	7301	42584861
Drug hypersensitivity	24.84	14.66	19	29154	99370	42492792
Procedural pneumothorax	24.80	14.66	6	29167	46	42592116
Cardio-respiratory arrest	24.74	14.66	5	29168	58631	42533531
Septic embolus	24.46	14.66	14	29159	1391	42590771
Splenic infarction	24.18	14.66	17	29156	2414	42589748
Retinal ischaemia	24.11	14.66	10	29163	489	42591673
Mastication disorder	23.91	14.66	15	29158	1761	42590401
Blast cells present	23.84	14.66	10	29163	503	42591659
Flatulence	23.83	14.66	53	29120	25099	42567063
Serum ferritin increased	23.80	14.66	27	29146	7192	42584970
Infectious thyroiditis	23.70	14.66	7	29166	122	42592040
Weight increased	23.42	14.66	140	29033	107843	42484319
Viral haemorrhagic cystitis	23.32	14.66	15	29158	1839	42590323
Vanishing bile duct syndrome	23.19	14.66	15	29158	1856	42590306
Gastrointestinal mucormycosis	22.91	14.66	9	29164	382	42591780
Depressed level of consciousness	22.67	14.66	3	29170	47967	42544195
Plasma cell myeloma	22.43	14.66	3	29170	47575	42544587
Skin lesion	22.18	14.66	54	29119	27120	42565042
Hallucination	22.10	14.66	6	29167	57501	42534661
Disease progression	22.04	14.66	171	29002	143485	42448677
Malignant neoplasm progression	22.04	14.66	25	29148	108375	42483787
Enterococcal sepsis	21.99	14.66	15	29158	2029	42590133
Septic shock	21.93	14.66	122	29051	91550	42500612
Blood product transfusion dependent	21.63	14.66	9	29164	444	42591718
Spleen disorder	21.45	14.66	12	29161	1141	42591021
Asthma	21.28	14.66	8	29165	62306	42529856
Chronic graft versus host disease in liver	21.06	14.66	10	29163	676	42591486
Epstein-Barr virus infection reactivation	20.78	14.66	16	29157	2611	42589551
Varicella keratitis	20.76	14.66	4	29169	8	42592154
Treatment failure	20.41	14.66	91	29082	62533	42529629
Sepsis	20.24	14.66	217	28956	199117	42393045
Staphylococcal bacteraemia	20.15	14.66	31	29142	11090	42581072
Lip ulceration	20.13	14.66	11	29162	999	42591163
Disease recurrence	20.12	14.66	55	29118	29623	42562539
Urticaria	20.01	14.66	13	29160	74023	42518139
Atypical mycobacterial lymphadenitis	19.87	14.66	4	29169	11	42592151
Babesiosis	19.66	14.66	7	29166	225	42591937
Somnolence	19.66	14.66	42	29131	141063	42451099
Thrombocytosis	19.50	14.66	20	29153	4755	42587407
Pneumonia adenoviral	19.41	14.66	8	29165	385	42591777
Seizure	19.32	14.66	33	29140	120528	42471634
Disseminated mycobacterium avium complex infection	19.23	14.66	7	29166	240	42591922
Osteonecrosis	19.23	14.66	37	29136	15828	42576334
Loss of consciousness	19.10	14.66	21	29152	92333	42499829
Pneumonia respiratory syncytial viral	19.03	14.66	12	29161	1422	42590740
Hepatitis toxic	18.93	14.66	15	29158	2552	42589610
Cytomegalovirus viraemia	18.91	14.66	29	29144	10348	42581814
Musculoskeletal stiffness	18.77	14.66	8	29165	57757	42534405
Bacteraemia	18.59	14.66	48	29125	24992	42567170
Serum ferritin abnormal	18.48	14.66	7	29166	269	42591893
Bacterial translocation	18.47	14.66	9	29164	644	42591518
Cardiac arrest	18.37	14.66	29	29144	109291	42482871
Pyomyositis	18.35	14.66	7	29166	274	42591888
Renal infarct	18.34	14.66	13	29160	1870	42590292
Aggression	18.15	14.66	4	29169	44159	42548003
Chronic graft versus host disease in intestine	18.15	14.66	8	29165	455	42591707
Myocardial infarction	18.04	14.66	36	29137	123973	42468189
Gastroenteritis Escherichia coli	17.97	14.66	10	29163	941	42591221
Herpes zoster	17.93	14.66	63	29110	38814	42553348
Feeding intolerance	17.75	14.66	7	29166	300	42591862
Enterocolitis infectious	17.73	14.66	13	29160	1970	42590192
Fusarium infection	17.72	14.66	12	29161	1604	42590558
Venoocclusive liver disease	17.67	14.66	28	29145	10274	42581888
Anxiety	17.61	14.66	34	29139	118526	42473636
Brain herniation	17.56	14.66	19	29154	4804	42587358
Steroid diabetes	17.54	14.66	15	29158	2837	42589325
Hepatorenal syndrome	17.53	14.66	15	29158	2839	42589323
Infection	17.52	14.66	134	29039	111934	42480228
Chest discomfort	17.43	14.66	11	29162	63605	42528557
Chronic myeloid leukaemia	17.18	14.66	14	29159	2478	42589684
Basophil count increased	17.11	14.66	9	29164	757	42591405
Diabetes mellitus	17.00	14.66	10	29163	60077	42532085
Hyponatraemia	16.97	14.66	27	29146	101435	42490727
Disseminated varicella zoster virus infection	16.95	14.66	9	29164	772	42591390
Blood creatine phosphokinase increased	16.85	14.66	6	29167	48332	42543830
Mycobacterium avium complex infection	16.77	14.66	15	29158	3012	42589150
Corneal lesion	16.62	14.66	5	29168	93	42592069
Haematoma infection	16.61	14.66	10	29163	1091	42591071
SARS-CoV-2 RNA	16.50	14.66	4	29169	31	42592131
Blood lactate dehydrogenase increased	16.37	14.66	47	29126	26034	42566128
Pneumonia aspiration	16.17	14.66	7	29166	50071	42542091
Haemorrhage	16.11	14.66	83	29090	60480	42531682
Blood pressure decreased	16.10	14.66	10	29163	58322	42533840
Blood immunoglobulin G decreased	15.95	14.66	13	29160	2301	42589861
Portal hypertension	15.95	14.66	18	29155	4769	42587393
Joint abscess	15.90	14.66	6	29167	228	42591934
Anorectal cellulitis	15.87	14.66	4	29169	37	42592125
Squamous cell carcinoma of skin	15.82	14.66	30	29143	12696	42579466
Brain abscess	15.81	14.66	17	29156	4267	42587895
Pancytopenia	15.81	14.66	136	29037	117607	42474555
Bone marrow transplant	15.75	14.66	10	29163	1199	42590963
Atypical mycobacterial pneumonia	15.66	14.66	6	29167	238	42591924
Skin cancer	15.48	14.66	28	29145	11434	42580728
Central nervous system haemorrhage	15.43	14.66	5	29168	120	42592042
Haematoma	15.23	14.66	48	29125	27975	42564187
Hepatic vein occlusion	15.20	14.66	6	29167	258	42591904
Oral lichenoid reaction	15.20	14.66	5	29168	126	42592036
Lichenoid keratosis	15.15	14.66	16	29157	3934	42588228
Tremor	15.10	14.66	27	29146	96902	42495260
Peripheral T-cell lymphoma unspecified recurrent	15.08	14.66	4	29169	46	42592116
Electrocardiogram QT prolonged	15.01	14.66	7	29166	47938	42544224
Increased appetite	14.99	14.66	24	29149	8882	42583280
Fungal infection	14.84	14.66	38	29135	19684	42572478
Haematocrit increased	14.78	14.66	13	29160	2554	42589608
Respiratory failure	14.67	14.66	143	29030	127989	42464173

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Splenomegaly	752.98	13.60	315	49452	24183	110515349
Platelet count decreased	591.48	13.60	618	49149	229825	110309707
Haemoglobin decreased	535.33	13.60	608	49159	248119	110291413
Platelet count increased	479.34	13.60	235	49532	26099	110513433
Off label use	409.39	13.60	1536	48231	1498649	109040883
Anaemia	388.52	13.60	797	48970	546289	109993243
Febrile neutropenia	345.03	13.60	556	49211	316211	110223321
Death	313.53	13.60	851	48916	698018	109841514
Graft versus host disease in gastrointestinal tract	287.86	13.60	119	49648	8849	110530683
Cytomegalovirus infection reactivation	250.74	13.60	135	49632	18198	110521334
Graft versus host disease in skin	243.03	13.60	103	49664	8151	110531381
Graft versus host disease	231.02	13.60	129	49638	18677	110520855
Adenovirus infection	226.97	13.60	107	49660	10887	110528645
Thrombocytopenia	225.81	13.60	490	49277	348395	110191137
White blood cell count increased	206.61	13.60	236	49531	96606	110442926
Thrombotic microangiopathy	197.68	13.60	137	49630	29012	110510520
Acute graft versus host disease	187.83	13.60	99	49668	12782	110526750
Graft versus host disease in liver	184.58	13.60	61	49706	2404	110537128
Myelofibrosis	183.29	13.60	64	49703	2987	110536545
Acute myeloid leukaemia	179.72	13.60	144	49623	37966	110501566
Disease propensity	174.38	13.60	26	49741	0	110539532
Bronchiolitis obliterans syndrome	174.29	13.60	44	49723	646	110538886
Drug ineffective for unapproved indication	158.73	13.60	213	49554	102625	110436907
Red blood cell count decreased	154.90	13.60	169	49598	65754	110473778
Product use in unapproved indication	148.01	13.60	490	49277	446887	110092645
Cytomegalovirus infection	144.64	13.60	149	49618	54295	110485237
Stenotrophomonas infection	139.62	13.60	63	49704	5795	110533737
Acute graft versus host disease in intestine	138.72	13.60	62	49705	5577	110533955
Iron overload	124.92	13.60	44	49723	2107	110537425
Drug effective for unapproved indication	123.76	13.60	78	49689	14089	110525443
Chronic graft versus host disease in skin	123.76	13.60	46	49721	2573	110536959
Full blood count abnormal	121.88	13.60	138	49629	55914	110483618
Cytopenia	121.57	13.60	104	49663	30012	110509520
Epstein-Barr virus infection reactivation	120.35	13.60	51	49716	4033	110535499
BK virus infection	119.13	13.60	74	49693	13032	110526500
Drug hypersensitivity	117.10	13.60	30	49737	454060	110085472
Rheumatoid arthritis	116.93	13.60	4	49763	299609	110239923
Herpes simplex	116.15	13.60	78	49689	15686	110523846
Platelet count abnormal	114.08	13.60	56	49711	6226	110533306
Dermatitis atopic	113.00	13.60	93	49674	25448	110514084
Aspergillus infection	112.77	13.60	93	49674	25523	110514009
Product dose omission issue	108.59	13.60	355	49412	321427	110218105
Acute graft versus host disease in skin	103.63	13.60	63	49704	10677	110528855
Haematocrit decreased	103.61	13.60	138	49629	65979	110473553
Synovitis	102.46	13.60	5	49762	274087	110265445
Systemic lupus erythematosus	100.66	13.60	3	49764	254335	110285197
Multiple organ dysfunction syndrome	97.83	13.60	213	49554	151497	110388035
Completed suicide	95.41	13.60	3	49764	242378	110297154
Chronic graft versus host disease	95.19	13.60	57	49710	9400	110530132
Joint swelling	92.14	13.60	42	49725	442803	110096729
Enterovirus infection	89.71	13.60	37	49730	2733	110536799
Blast cell count increased	89.43	13.60	32	49735	1605	110537927
Graft versus host disease in lung	89.22	13.60	30	49737	1248	110538284
Leukocytosis	88.43	13.60	115	49652	53713	110485819
Hypersensitivity	87.72	13.60	36	49731	403962	110135570
Bronchopulmonary aspergillosis	87.13	13.60	86	49681	29777	110509755
Second primary malignancy	86.72	13.60	69	49698	17999	110521533
Disease progression	85.69	13.60	273	49494	243761	110295771
Contraindicated product administered	85.44	13.60	7	49760	248260	110291272
Pericarditis	85.22	13.60	3	49764	219111	110320421
Arthropathy	84.39	13.60	14	49753	287508	110252024
Chronic graft versus host disease oral	84.07	13.60	23	49744	468	110539064
Polyomavirus-associated nephropathy	84.02	13.60	50	49717	8151	110531381
Haemophagocytic lymphohistiocytosis	83.14	13.60	86	49681	31473	110508059
Haematocrit increased	80.59	13.60	41	49726	4918	110534614
Sepsis	79.80	13.60	325	49442	327021	110212511
Musculoskeletal stiffness	79.13	13.60	15	49752	279807	110259725
Varicella zoster virus infection	76.34	13.60	43	49724	6325	110533207
Viral haemorrhagic cystitis	76.10	13.60	35	49732	3364	110536168
Glossodynia	74.38	13.60	7	49760	221997	110317535
Rhinovirus infection	74.31	13.60	53	49714	11736	110527796
Urticaria	71.53	13.60	27	49740	318830	110220702
Therapeutic product effect decreased	71.46	13.60	12	49755	244304	110295228
Blood lactate dehydrogenase increased	68.63	13.60	92	49675	44242	110495290
Respiratory failure	68.51	13.60	233	49534	215099	110324433
Cystitis haemorrhagic	68.15	13.60	51	49716	12158	110527374
Acute graft versus host disease in liver	67.99	13.60	29	49738	2330	110537202
Acute leukaemia	67.79	13.60	27	49740	1822	110537710
Epistaxis	67.53	13.60	168	49599	130204	110409328
Helicobacter infection	65.83	13.60	4	49763	181873	110357659
Lower respiratory tract infection	64.69	13.60	15	49752	243091	110296441
Respiratory syncytial virus infection	64.61	13.60	53	49714	14431	110525101
Chronic graft versus host disease in eye	64.00	13.60	18	49749	407	110539125
White blood cell count decreased	63.38	13.60	237	49530	229153	110310379
Toxicity to various agents	63.10	13.60	74	49693	480481	110059051
Overdose	63.06	13.60	14	49753	233780	110305752
Cytomegalovirus viraemia	62.99	13.60	57	49710	17707	110521825
Maternal exposure during pregnancy	61.63	13.60	19	49748	254864	110284668
Enterococcal bacteraemia	61.40	13.60	33	49734	4428	110535104
Folliculitis	59.75	13.60	4	49763	167649	110371883
Septic shock	59.68	13.60	181	49586	157347	110382185
Exposure during pregnancy	59.65	13.60	4	49763	167420	110372112
Confusional state	58.55	13.60	75	49692	468605	110070927
Haemosiderosis	58.35	13.60	18	49749	566	110538966
Asthma	58.15	13.60	20	49747	250271	110289261
Pulmonary mucormycosis	57.35	13.60	25	49742	2118	110537414
Immunosuppression	57.18	13.60	54	49713	17705	110521827
Rebound effect	55.45	13.60	49	49718	14757	110524775
Pneumatosis intestinalis	55.27	13.60	39	49728	8490	110531042
Squamous cell carcinoma of skin	54.80	13.60	52	49715	17151	110522381
Pancytopenia	54.15	13.60	212	49555	209401	110330131
Swelling	54.12	13.60	47	49720	350994	110188538
Squamous cell carcinoma	53.54	13.60	53	49714	18410	110521122
Injury	53.43	13.60	8	49759	177257	110362275
Mobility decreased	53.41	13.60	20	49747	237402	110302130
Myeloproliferative neoplasm	53.20	13.60	21	49746	1384	110538148
Emphysematous cholecystitis	52.70	13.60	12	49755	110	110539422
Wound	52.31	13.60	20	49747	234417	110305115
Hepatic enzyme increased	51.89	13.60	41	49726	320851	110218681
Wheezing	51.82	13.60	25	49742	255205	110284327
Alveolar proteinosis	51.39	13.60	21	49746	1515	110538017
Muscle injury	51.25	13.60	3	49764	140804	110398728
Product availability issue	50.95	13.60	36	49731	7854	110531678
Contusion	50.85	13.60	224	49543	233137	110306395
Chimerism	50.18	13.60	14	49753	307	110539225
Staphylococcal infection	49.45	13.60	102	49665	69842	110469690
Pneumonia adenoviral	48.57	13.60	16	49751	624	110538908
Drug interaction	48.31	13.60	95	49672	500088	110039444
Thrombocytosis	48.24	13.60	39	49728	10405	110529127
Pain	47.99	13.60	244	49523	954711	109584821
Atypical mycobacterial lymphadenitis	47.41	13.60	9	49758	29	110539503
Necrotising retinitis	47.26	13.60	20	49747	1576	110537956
Flatulence	46.62	13.60	84	49683	52065	110487467
Bursitis	46.59	13.60	3	49764	129915	110409617
Early satiety	46.43	13.60	21	49746	1942	110537590
Parainfluenzae virus infection	45.45	13.60	32	49735	6942	110532590
Psoriasis	45.37	13.60	5	49762	139988	110399544
Epstein-Barr viraemia	45.17	13.60	25	49742	3554	110535978
Mucosal inflammation	44.72	13.60	119	49648	96022	110443510
Haemoglobin increased	44.04	13.60	35	49732	9112	110530420
Pneumonia	43.99	13.60	594	49173	876120	109663412
Microangiopathy	43.77	13.60	23	49744	2949	110536583
Impaired healing	43.53	13.60	17	49750	196700	110342832
Osteoarthritis	43.45	13.60	14	49753	182609	110356923
Increased appetite	43.44	13.60	43	49724	14934	110524598
Nocardiosis	43.42	13.60	32	49735	7454	110532078
Venoocclusive liver disease	42.89	13.60	43	49724	15164	110524368
Chronic graft versus host disease in liver	42.85	13.60	16	49751	906	110538626
Bacteraemia	42.74	13.60	72	49695	42318	110497214
Gastrointestinal mucormycosis	42.43	13.60	15	49752	726	110538806
Fusarium infection	42.40	13.60	22	49745	2749	110536783
Pneumonia fungal	42.13	13.60	42	49725	14712	110524820
Basophil count increased	41.66	13.60	19	49748	1791	110537741
Pyrexia	40.79	13.60	598	49169	897667	109641865
NPM1 gene mutation	40.74	13.60	10	49757	130	110539402
Central nervous system viral infection	40.71	13.60	12	49755	322	110539210
Epstein-Barr virus infection	40.49	13.60	46	49721	18692	110520840
Idiopathic pneumonia syndrome	39.80	13.60	15	49752	872	110538660
Chronic graft versus host disease in intestine	39.63	13.60	14	49753	676	110538856
Herpes zoster	39.61	13.60	123	49644	108256	110431276
Drug resistance	39.60	13.60	82	49685	56292	110483240
Staphylococcal bacteraemia	39.56	13.60	43	49724	16645	110522887
Acute myeloid leukaemia recurrent	39.23	13.60	26	49741	5113	110534419
Herpes simplex pneumonia	38.79	13.60	12	49755	381	110539151
Bradycardia	38.67	13.60	11	49756	155506	110384026
Loss of personal independence in daily activities	38.45	13.60	10	49757	150010	110389522
Drug intolerance	37.71	13.60	79	49688	406433	110133099
Gastrooesophageal reflux disease	37.49	13.60	17	49750	179959	110359573
Skin lesion	37.33	13.60	76	49691	51555	110487977
Liver injury	36.73	13.60	11	49756	150402	110389130
Leukaemia	36.70	13.60	29	49738	7489	110532043
Chemokine increased	36.54	13.60	7	49760	24	110539508
Type 2 diabetes mellitus	36.52	13.60	17	49750	177215	110362317
Disease recurrence	36.51	13.60	83	49684	60701	110478831
Serum ferritin increased	36.20	13.60	35	49732	11812	110527720
Disseminated mucormycosis	35.98	13.60	18	49749	2084	110537448
Joint range of motion decreased	35.58	13.60	6	49761	121826	110417706
Hypotension	35.53	13.60	119	49648	523730	110015802
Arthralgia	35.37	13.60	206	49561	779426	109760106
Transfusion	35.12	13.60	50	49717	25422	110514110
Urethral polyp	34.97	13.60	8	49759	75	110539457
Anxiety	34.64	13.60	64	49703	345014	110194518
Alopecia	34.58	13.60	70	49697	364683	110174849
Pseudomonas infection	34.53	13.60	52	49715	27801	110511731
Haemoglobin abnormal	34.02	13.60	30	49737	9008	110530524
Respiratory tract inflammation	34.01	13.60	14	49753	1029	110538503
Lip dry	33.93	13.60	3	49764	100080	110439452
Type III immune complex mediated reaction	33.88	13.60	14	49753	1039	110538493
Osteonecrosis	33.60	13.60	57	49710	33684	110505848
Eye infection fungal	33.32	13.60	12	49755	613	110538919
Angioedema	33.27	13.60	3	49764	98497	110441035
Splenectomy	32.93	13.60	13	49754	857	110538675
Urinary tract infection bacterial	32.84	13.60	28	49739	8039	110531493
Enterocolitis viral	32.77	13.60	13	49754	868	110538664
Bone pain	32.73	13.60	83	49684	65050	110474482
Wrong technique in product usage process	32.72	13.60	100	49667	87248	110452284
Sinusitis	32.55	13.60	52	49715	296636	110242896
Pneumoretroperitoneum	32.45	13.60	9	49758	193	110539339
Babesiosis	32.12	13.60	11	49756	484	110539048
Depressed level of consciousness	31.76	13.60	6	49761	112272	110427260
Hypogammaglobulinaemia	31.58	13.60	42	49725	20034	110519498
Blood bilirubin increased	31.33	13.60	90	49677	75882	110463650
Interleukin level increased	31.08	13.60	15	49752	1606	110537926
Ill-defined disorder	30.87	13.60	16	49751	156837	110382695
Bacterial sepsis	30.36	13.60	30	49737	10396	110529136
Intentional product misuse	30.21	13.60	11	49756	132893	110406639
Klebsiella infection	30.17	13.60	41	49726	19968	110519564
Acute respiratory distress syndrome	30.15	13.60	71	49696	53127	110486405
Viraemia	29.50	13.60	20	49747	4082	110535450
Gastroenteritis adenovirus	29.44	13.60	10	49757	429	110539103
Rhabdomyolysis	29.05	13.60	9	49758	120392	110419140
Gastrointestinal disorder	28.88	13.60	40	49727	241912	110297620
Suicidal ideation	28.86	13.60	4	49763	93933	110445599
Eczema herpeticum	28.45	13.60	10	49757	476	110539056
Haemorrhagic diathesis	28.42	13.60	25	49742	7483	110532049
Splenic infarction	28.34	13.60	20	49747	4354	110535178
Thyroid gland abscess	28.17	13.60	7	49760	96	110539436
White blood cell count abnormal	28.16	13.60	24	49743	6885	110532647
Blast cells present	28.11	13.60	12	49755	966	110538566
Agitation	28.09	13.60	8	49759	113043	110426489
Cytomegalovirus colitis	27.71	13.60	24	49743	7037	110532495
Pyomyositis	27.52	13.60	11	49756	749	110538783
Organising pneumonia	27.49	13.60	33	49734	14210	110525322
Therapeutic response unexpected	27.43	13.60	43	49724	23800	110515732
Citrobacter infection	27.32	13.60	13	49754	1349	110538183
Portal hypertension	27.31	13.60	26	49741	8611	110530921
Neutropenia	27.29	13.60	273	49494	374347	110165185
Haematocrit abnormal	27.21	13.60	14	49753	1719	110537813
Drug ineffective	26.81	13.60	883	48884	1519657	109019875
Blister	26.72	13.60	38	49729	227338	110312194
Therapeutic product effect incomplete	26.71	13.60	37	49730	223768	110315764
Gait inability	26.70	13.60	14	49753	136362	110403170
Basophil percentage increased	26.10	13.60	8	49759	246	110539286
Sciatica	26.00	13.60	5	49762	92394	110447138
Myopathy	25.97	13.60	43	49724	24917	110514615
Hypoaesthesia	25.94	13.60	65	49702	314158	110225374
Posterior reversible encephalopathy syndrome	25.86	13.60	51	49716	33810	110505722
Venoocclusive disease	25.77	13.60	22	49745	6328	110533204
Wound infection	25.55	13.60	6	49761	96459	110443073
Musculoskeletal pain	25.28	13.60	27	49740	182996	110356536
Enterocolitis infectious	25.27	13.60	17	49750	3427	110536105
Ejection fraction abnormal	25.20	13.60	17	49750	3443	110536089
Mycobacterium avium complex infection	25.16	13.60	21	49746	5856	110533676
Product administered to patient of inappropriate age	25.04	13.60	24	49743	8012	110531520
JC virus infection	24.95	13.60	20	49747	5270	110534262
Obesity	24.73	13.60	10	49757	113341	110426191
Blood cholesterol increased	24.71	13.60	28	49739	184757	110354775
Gastroenteritis Escherichia coli	24.69	13.60	12	49755	1305	110538227
Weight increased	24.65	13.60	293	49474	419351	110120181
Blood immunoglobulin G decreased	24.59	13.60	20	49747	5380	110534152
Blast cell crisis	24.57	13.60	7	49760	166	110539366
Tongue neoplasm malignant stage unspecified	24.50	13.60	12	49755	1327	110538205
Depression	24.41	13.60	68	49699	317267	110222265
Haematotoxicity	24.23	13.60	38	49729	21044	110518488
Vanishing bile duct syndrome	24.12	13.60	16	49751	3152	110536380
Intentional product use issue	23.98	13.60	47	49720	247859	110291673
Renal-limited thrombotic microangiopathy	23.62	13.60	9	49758	539	110538993
Diarrhoea haemorrhagic	23.51	13.60	32	49735	15607	110523925
Enterococcal sepsis	23.47	13.60	16	49751	3296	110536236
Infectious thyroiditis	23.43	13.60	7	49760	197	110539335
Septic embolus	23.36	13.60	14	49753	2312	110537220
Malaise	23.28	13.60	192	49575	671627	109867905
Epilepsy	23.28	13.60	8	49759	100201	110439331
Anorectal cellulitis	23.23	13.60	6	49761	97	110539435
Fungal endocarditis	23.18	13.60	10	49757	826	110538706
Primary myelofibrosis	23.13	13.60	7	49760	206	110539326
Optic neuropathy	22.80	13.60	18	49749	4640	110534892
Promyelocyte count increased	22.79	13.60	5	49762	38	110539494
Metapneumovirus infection	22.72	13.60	14	49753	2430	110537102
Road traffic accident	22.59	13.60	10	49757	107388	110432144
Varicella keratitis	22.44	13.60	4	49763	8	110539524
Haemophilus bacteraemia	22.28	13.60	7	49760	234	110539298
Hyperuricaemia	22.25	13.60	30	49737	14501	110525031
Paraesthesia	22.21	13.60	58	49709	276463	110263069
Erythropoiesis abnormal	22.20	13.60	9	49758	636	110538896
Product quality issue	22.14	13.60	4	49763	77295	110462237
Post transplant lymphoproliferative disorder	22.05	13.60	31	49736	15582	110523950
Hallucination	22.05	13.60	9	49758	101423	110438109
Cerebral artery embolism	21.96	13.60	13	49754	2099	110537433
Parvovirus infection	21.94	13.60	10	49757	941	110538591
Lichenoid keratosis	21.91	13.60	20	49747	6282	110533250
Skin cancer	21.76	13.60	33	49734	17751	110521781
Flushing	21.64	13.60	10	49757	104726	110434806
Hypercholesterolaemia	21.54	13.60	7	49760	90830	110448702
Graft versus host disease in eye	21.44	13.60	8	49759	452	110539080
Haemorrhage	21.41	13.60	100	49667	106592	110432940
Procedural pneumothorax	21.40	13.60	6	49761	134	110539398
Retinal ischaemia	21.40	13.60	10	49757	997	110538535
Small intestine gangrene	21.39	13.60	5	49762	52	110539480
Brain herniation	21.29	13.60	23	49744	8840	110530692
Pneumonia respiratory syncytial viral	21.21	13.60	14	49753	2735	110536797
Enterococcal infection	21.07	13.60	35	49732	20331	110519201
Steroid diabetes	20.90	13.60	18	49749	5236	110534296
Pulmonary haemorrhage	20.80	13.60	31	49736	16425	110523107
Eye infection toxoplasmal	20.77	13.60	9	49758	751	110538781
Red cell distribution width increased	20.61	13.60	32	49735	17570	110521962
Pathogen resistance	20.51	13.60	32	49735	17640	110521892
C-reactive protein increased	20.48	13.60	42	49725	217877	110321655
Infective aneurysm	20.43	13.60	11	49756	1481	110538051
Peripheral swelling	20.35	13.60	103	49664	403931	110135601
Bladder hypertrophy	20.35	13.60	10	49757	1114	110538418
Spleen disorder	20.30	13.60	12	49755	1932	110537600
Mastication disorder	20.24	13.60	15	49752	3523	110536009
Hepatic vein occlusion	20.23	13.60	7	49760	318	110539214
Dry skin	20.22	13.60	99	49668	107554	110431978
Cardiac arrest	20.17	13.60	36	49731	196717	110342815
Scedosporium infection	20.14	13.60	13	49754	2445	110537087
Chest pain	20.08	13.60	94	49673	376281	110163251
Atypical mycobacterial pneumonia	20.08	13.60	7	49760	325	110539207
Syncope	19.93	13.60	38	49729	202498	110337034
Fungal infection	19.81	13.60	59	49708	50747	110488785
Hepatomegaly	19.79	13.60	35	49732	21379	110518153
Extramedullary haemopoiesis	19.78	13.60	7	49760	340	110539192
Janus kinase 2 mutation	19.67	13.60	4	49763	20	110539512
Neck pain	19.55	13.60	16	49751	123114	110416418
Injection site erythema	19.45	13.60	9	49758	94167	110445365
Blood pressure increased	19.40	13.60	56	49711	258317	110281215
Red blood cell count abnormal	19.35	13.60	11	49756	1647	110537885
Fatigue	19.33	13.60	698	49069	1215260	109324272
Therapy non-responder	19.24	13.60	129	49638	157178	110382354
Oral herpes	19.20	13.60	47	49720	36033	110503499
Blood pressure fluctuation	19.14	13.60	5	49762	74819	110464713
Sedation	19.13	13.60	4	49763	69679	110469853
Myocardial oedema	19.09	13.60	8	49759	615	110538917
Basal cell carcinoma	19.02	13.60	54	49713	45216	110494316
Pneumocystis jirovecii pneumonia	18.97	13.60	52	49715	42683	110496849
Discomfort	18.84	13.60	43	49724	214664	110324868
Hepatorenal syndrome	18.80	13.60	16	49751	4581	110534951
Plasma cell myeloma	18.59	13.60	3	49764	62933	110476599
Drug-induced liver injury	18.58	13.60	16	49751	120051	110419481
Chest discomfort	18.56	13.60	31	49736	173817	110365715
Cardio-respiratory arrest	18.46	13.60	15	49752	115821	110423711
Blood erythropoietin decreased	18.40	13.60	4	49763	29	110539503
Eye infection bacterial	18.31	13.60	7	49760	423	110539109
Haemorrhage urinary tract	18.05	13.60	13	49754	2923	110536609
MAGIC syndrome	18.04	13.60	3	49764	3	110539529
Migraine	17.96	13.60	31	49736	171621	110367911
SARS-CoV-2 RNA	17.94	13.60	4	49763	33	110539499
Clostridial sepsis	17.91	13.60	9	49758	1052	110538480
Transplant failure	17.88	13.60	17	49750	5618	110533914
Red blood cell count increased	17.87	13.60	16	49751	4902	110534630
Pulmonary fibrosis	17.83	13.60	12	49755	102030	110437502
Cystitis viral	17.80	13.60	10	49757	1463	110538069
Bone tuberculosis	17.79	13.60	8	49759	730	110538802
Chronic myeloid leukaemia	17.74	13.60	15	49752	4258	110535274
Energy increased	17.56	13.60	14	49753	3660	110535872
Loss of consciousness	17.48	13.60	39	49728	196267	110343265
Human herpesvirus 6 infection	17.45	13.60	18	49749	6563	110532969
Renal vein thrombosis	17.41	13.60	9	49758	1116	110538416
Bacteroides bacteraemia	17.38	13.60	5	49762	123	110539409
Pulmonary tuberculosis	17.36	13.60	21	49746	9118	110530414
Neutrophil count increased	17.24	13.60	44	49723	34608	110504924
Hepatitis toxic	17.17	13.60	17	49750	5904	110533628
Prescribed overdose	17.13	13.60	9	49758	87572	110451960
Disseminated mycobacterium avium complex infection	17.05	13.60	7	49760	511	110539021
Brain abscess	17.01	13.60	18	49749	6756	110532776
Bacterial infection	16.58	13.60	52	49715	45984	110493548
Neutrophil count decreased	16.52	13.60	102	49665	120839	110418693
Lip ulceration	16.39	13.60	12	49755	2766	110536766
Renal infarct	16.36	13.60	13	49754	3382	110536150
Mucormycosis	16.36	13.60	22	49745	10606	110528926
Disseminated varicella zoster virus infection	16.31	13.60	9	49758	1272	110538260
Abdominal discomfort	16.29	13.60	107	49660	393751	110145781
Yellow skin	16.21	13.60	14	49753	4088	110535444
Myelocyte count increased	16.16	13.60	8	49759	906	110538626
Peripheral T-cell lymphoma unspecified recurrent	16.02	13.60	4	49763	56	110539476
Mesenteric artery thrombosis	15.84	13.60	8	49759	945	110538587
Cachexia	15.72	13.60	24	49743	12981	110526551
Sleep disorder	15.69	13.60	42	49725	198602	110340930
Autoimmune disorder	15.61	13.60	5	49762	65478	110474054
Pneumonia klebsiella	15.56	13.60	17	49750	6615	110532917
Somnolence	15.45	13.60	75	49692	297374	110242158
Acute respiratory failure	15.44	13.60	71	49696	75189	110464343
Therapy partial responder	15.37	13.60	44	49723	37017	110502515
Monocyte count increased	15.33	13.60	24	49743	13269	110526263
Respirovirus test	15.30	13.60	3	49764	12	110539520
Engraftment syndrome	15.30	13.60	10	49757	1922	110537610
Adverse drug reaction	15.22	13.60	15	49752	105544	110433988
Adenocarcinoma metastatic	15.22	13.60	6	49761	394	110539138
Stress	15.16	13.60	15	49752	105333	110434199
Aggression	15.07	13.60	4	49763	59206	110480326
Bacterial translocation	15.03	13.60	9	49758	1483	110538049
Joint abscess	15.01	13.60	7	49760	694	110538838
Hypothyroidism	15	13.60	7	49760	72892	110466640
Hepatosplenomegaly	14.97	13.60	17	49750	6902	110532630
Haematoma	14.96	13.60	59	49708	58417	110481115
Hypergammaglobulinaemia benign monoclonal	14.83	13.60	8	49759	1081	110538451
Pneumonia bacterial	14.82	13.60	35	49732	26226	110513306
Blood pressure decreased	14.78	13.60	18	49749	115073	110424459
Gout	14.77	13.60	43	49724	36523	110503009
Increased tendency to bruise	14.64	13.60	22	49745	11736	110527796
Post herpetic neuralgia	14.56	13.60	12	49755	3289	110536243
Clostridial infection	14.52	13.60	16	49751	6286	110533246
Nasopharyngitis	14.43	13.60	111	49656	394250	110145282
Hypertriglyceridaemia	14.41	13.60	26	49741	16128	110523404
Arthritis	14.35	13.60	34	49733	167552	110371980
Serum ferritin abnormal	14.30	13.60	6	49761	463	110539069
Laboratory test abnormal	14.26	13.60	48	49719	44031	110495501
Exercise tolerance decreased	14.21	13.60	22	49745	12045	110527487
Feeding intolerance	14.21	13.60	8	49759	1176	110538356
Bone marrow transplant	14.15	13.60	9	49758	1651	110537881
Urinary tract candidiasis	14.11	13.60	8	49759	1191	110538341
Disseminated blastomycosis	14.10	13.60	6	49761	479	110539053
Clubbing	14.09	13.60	7	49760	798	110538734
Dry eye	14.04	13.60	56	49711	55737	110483795
Blood product transfusion dependent	13.98	13.60	6	49761	489	110539043
Red blood cell sedimentation rate increased	13.96	13.60	9	49758	78293	110461239
Acute graft versus host disease oral	13.96	13.60	4	49763	97	110539435
Dyspepsia	13.89	13.60	42	49725	190923	110348609
Drug reaction with eosinophilia and systemic symptoms	13.88	13.60	10	49757	82085	110457447
Weaning failure	13.84	13.60	7	49760	829	110538703
Cutaneous T-cell lymphoma recurrent	13.84	13.60	4	49763	100	110539432
Opportunistic infection	13.82	13.60	12	49755	3531	110536001
Hypertension	13.74	13.60	155	49612	509929	110029603
Abscess limb	13.71	13.60	18	49749	8479	110531053
Cerebral aspergillosis	13.71	13.60	10	49757	2292	110537240
Swollen tongue	13.71	13.60	5	49762	60357	110479175
Alpha haemolytic streptococcal infection	13.67	13.60	12	49755	3581	110535951
Vomiting	13.67	13.60	309	49458	910366	109629166

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D11AH09	DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Agents for dermatitis, excluding corticosteroids
ATC	L01EJ01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Janus-associated kinase (JAK) inhibitors
FDA MoA	N0000175076	Protein Kinase Inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
FDA MoA	N0000190857	Janus Kinase Inhibitors
FDA EPC	N0000190858	Janus Kinase Inhibitor
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:38068	antimalarial
CHEBI has role	CHEBI:50177	dermatologic drug
CHEBI has role	CHEBI:50748	antipsoriatic
CHEBI has role	CHEBI:76617	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
CHEBI has role	CHEBI:233423	antifibrotic agent
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:33281	antimicrobial agent
CHEBI has role	CHEBI:35705	immunosuppressive agent
CHEBI has role	CHEBI:35842	antirheumatic drug
CHEBI has role	CHEBI:64946	anti-HIV agent
CHEBI has role	CHEBI:75835	anti-anaemic agent

Related Drugs by ATC class:

D11AH Agents for dermatitis, excluding corticosteroids 11 drugs

abrocitinib alitretinoin crisaborole cromoglicic acid delgocitinib dupilumab lebrikizumab nemolizumab pimecrolimus tacrolimus tralokinumab

L01EJ Janus-associated kinase (JAK) inhibitors 3 drugs

fedratinib momelotinib pacritinib

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Splenomegaly	indication	16294009
Myelofibrosis	indication	52967002	DOID:4971
Vitiligo	indication	56727007	DOID:12306
Polycythemia vera	indication	109992005
Acute graft-versus-host disease	indication	402355000
Chronic graft-versus-host disease	indication	402356004
Myeloproliferative disorder	indication	425333006
Coronavirus infection	off-label use	186747009
Pregnancy, function	contraindication	289908002
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.44	acidic
pKa2	4.6	Basic
pKa3	2.37	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	10639310	Dec. 12, 2026	FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	9079912	Dec. 12, 2026	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	9079912	Dec. 12, 2026	FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	9974790	Dec. 12, 2026	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	9974790	Dec. 12, 2026	FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11744832	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11744832	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9206187	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9206187	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11744832	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11744832	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9206187	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9206187	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11744832	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11744832	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9206187	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9206187	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11744832	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11744832	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9206187	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9206187	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11744832	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11744832	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9206187	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9206187	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	10610530	June 12, 2028	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	10610530	June 12, 2028	FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	8822481	June 12, 2028	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	8822481	June 12, 2028	FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	10016429	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	10016429	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8829013	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8829013	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	10016429	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	10016429	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8829013	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8829013	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	10016429	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	10016429	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8829013	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8829013	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	10016429	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	10016429	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8829013	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8829013	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	10016429	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	10016429	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8822481	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8829013	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	8829013	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	10869870	May 20, 2031	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	10869870	May 20, 2031	FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	11219624	May 20, 2031	FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	11590136	May 20, 2031	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	11590136	May 20, 2031	FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576864	Nov. 14, 2033	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11576865	Nov. 14, 2033	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11896717	Nov. 14, 2033	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	11337927	Jan. 17, 2034	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	11590138	June 10, 2040	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER, IN THE ABSENCE OF PHOTOTHERAPY, WHEREIN THE VITILIGO AFFECTS AT LEAST ONE OF THE LOWER EXTREMITIES, TRUNK, AND FEET OF THE PATIENT
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	12233067	July 28, 2040	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER, WHEREIN THE DEPIGMENTED AREA IS ≥ 0.5% BSA ON THE FACE, ≥ 3% BSA ON NON-FACIAL AREAS, AND NOT >10% BSA ON TOTAL BODY AREA
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	11510923	Sept. 4, 2040	FOR TOPICAL TREATMENT OF MODERATE AD IN NON-IMMUNOCOMPROMISED PATIENTS, WITH BASELINE BSA OF 3-20% AND ITCH NRS SCORE OF ≥4, WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	11590137	Sept. 4, 2040	FOR TOPICAL TREATMENT OF MODERATE AD IN NON-IMMUNOCOMPROMISED PATIENTS, WITH BASELINE BSA OF 3-20% AND ITCH NRS SCORE OF ≥4, WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	12589096	Sept. 4, 2040	FOR TOPICAL TREATMENT OF MODERATE AD IN NON-IMMUNOCOMPROMISED PATIENTS, WITH BASELINE BSA OF 3-20% AND ITCH NRS SCORE OF ≥4, WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	11602536	May 5, 2041	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER, IN THE ABSENCE OF LASER OR PHOTOTHERAPY, WHEREIN THE VITILIGO AFFECTS AT LEAST ONE OF THE LOWER EXTREMITIES, TRUNK, AND FEET OF THE PATIENT

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	July 18, 2025	INDICATED FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Dec. 19, 2025	REVISIONS TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULTS OF STUDY INCB 18424-269
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Dec. 19, 2025	REVISIONS TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULTS OF STUDY INCB 18424-269
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Dec. 19, 2025	REVISIONS TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULTS OF STUDY INCB 18424-269
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Dec. 19, 2025	REVISIONS TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULTS OF STUDY INCB 18424-269
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Dec. 19, 2025	REVISIONS TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULTS OF STUDY INCB 18424-269
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	Jan. 18, 2026	PEDIATRIC EXCLUSIVITY
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	May 24, 2026	TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	May 24, 2026	TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	May 24, 2026	TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	May 24, 2026	TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	May 24, 2026	TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	June 19, 2026	PEDIATRIC EXCLUSIVITY
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	June 19, 2026	PEDIATRIC EXCLUSIVITY
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	June 19, 2026	PEDIATRIC EXCLUSIVITY
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	June 19, 2026	PEDIATRIC EXCLUSIVITY
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	June 19, 2026	PEDIATRIC EXCLUSIVITY
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Nov. 24, 2026	PEDIATRIC EXCLUSIVITY
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Nov. 24, 2026	PEDIATRIC EXCLUSIVITY
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Nov. 24, 2026	PEDIATRIC EXCLUSIVITY
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Nov. 24, 2026	PEDIATRIC EXCLUSIVITY
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Nov. 24, 2026	PEDIATRIC EXCLUSIVITY
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	Sept. 18, 2028	NEW PATIENT POPULATION
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Sept. 22, 2028	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Sept. 22, 2028	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Sept. 22, 2028	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Sept. 22, 2028	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Sept. 22, 2028	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	Sept. 22, 2028	FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S). AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	Sept. 22, 2028	FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S). AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	Sept. 22, 2028	FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S). AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	Sept. 22, 2028	FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S). AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	Sept. 22, 2028	FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S). AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	March 22, 2029	PEDIATRIC EXCLUSIVITY
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	March 22, 2029	PEDIATRIC EXCLUSIVITY
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	March 22, 2029	PEDIATRIC EXCLUSIVITY
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	March 22, 2029	PEDIATRIC EXCLUSIVITY
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	March 22, 2029	PEDIATRIC EXCLUSIVITY
EQ 11MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	March 22, 2029	PEDIATRIC EXCLUSIVITY
EQ 22MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	March 22, 2029	PEDIATRIC EXCLUSIVITY
EQ 33MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	March 22, 2029	PEDIATRIC EXCLUSIVITY
EQ 44MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	March 22, 2029	PEDIATRIC EXCLUSIVITY
EQ 55MG BASE	JAKAFI XR	INCYTE CORP	N217180	May 1, 2026	RX	TABLET, EXTENDED RELEASE	ORAL	March 22, 2029	PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Tyrosine-protein kinase JAK2	Kinase	O60674	JAK2_HUMAN	INHIBITOR	Kd	10.44	CHEMBL	CHEMBL
Tyrosine-protein kinase JAK1	Kinase	P23458	JAK1_HUMAN	INHIBITOR	Ki	10.05	CHEMBL	CHEMBL
Tyrosine-protein kinase ABL1	Kinase	P00519	ABL1_HUMAN		Kd	5.96	CHEMBL
Mast/stem cell growth factor receptor Kit	Kinase	P10721	KIT_HUMAN		Kd	5.20	CHEMBL
Serine/threonine-protein kinase B-raf	Kinase	P15056	BRAF_HUMAN		Kd	5.66	CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret	Kinase	P07949	RET_HUMAN		Kd	6.72	CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Kinase	P15735	PHKG2_HUMAN		Kd	6	CHEMBL
Myosin light chain kinase, smooth muscle	Kinase	Q15746	MYLK_HUMAN		Kd	6.44	CHEMBL
Death-associated protein kinase 3	Kinase	O43293	DAPK3_HUMAN		Kd	7.05	CHEMBL
Histone deacetylase 6	Enzyme	Q9UBN7	HDAC6_HUMAN		IC50	7.82	CHEMBL
Calcium/calmodulin-dependent protein kinase type 1	Kinase	Q14012	KCC1A_HUMAN		Kd	6.33	CHEMBL
Mitogen-activated protein kinase 8	Kinase	P45983	MK08_HUMAN		Kd	5.32	CHEMBL
Rho-associated protein kinase 1	Kinase	Q13464	ROCK1_HUMAN		Kd	7.22	CHEMBL
Serine/threonine-protein kinase PLK1	Kinase	P53350	PLK1_HUMAN		Kd	6.89	CHEMBL
Death-associated protein kinase 2	Kinase	Q9UIK4	DAPK2_HUMAN		Kd	7.01	CHEMBL
High affinity nerve growth factor receptor	Kinase	P04629	NTRK1_HUMAN		Kd	5.82	CHEMBL
Rho-associated protein kinase 2	Kinase	O75116	ROCK2_HUMAN		Kd	7.28	CHEMBL
Protein kinase C alpha type	Kinase	P17252	KPCA_HUMAN		Kd	4.78	CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit delta	Kinase	Q13557	KCC2D_HUMAN		Kd	7.05	CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit gamma	Kinase	Q13555	KCC2G_HUMAN		Kd	7	CHEMBL
AP2-associated protein kinase 1	Kinase	Q2M2I8	AAK1_HUMAN		Kd	6.92	CHEMBL
Serine/threonine-protein kinase MARK2	Kinase	Q7KZI7	MARK2_HUMAN		Kd	6.18	CHEMBL
Ribosomal protein S6 kinase alpha-2	Kinase	Q15349	KS6A2_HUMAN		Kd	6.82	CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit beta	Kinase	Q13554	KCC2B_HUMAN		Kd	6.51	CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform	Kinase	Q16816	PHKG1_HUMAN		Kd	5.24	CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit alpha	Kinase	Q9UQM7	KCC2A_HUMAN		Kd	7.34	CHEMBL
Serine/threonine-protein kinase 17B	Kinase	O94768	ST17B_HUMAN		Kd	5.46	CHEMBL
Protein kinase C epsilon type	Kinase	Q02156	KPCE_HUMAN		Kd	6.28	CHEMBL
Serine/threonine-protein kinase PLK4	Kinase	O00444	PLK4_HUMAN		Kd	6.70	CHEMBL
Aurora kinase C	Kinase	Q9UQB9	AURKC_HUMAN		Kd	5.06	CHEMBL
Dual specificity protein kinase TTK	Kinase	P33981	TTK_HUMAN		Kd	6.32	CHEMBL
Serine/threonine-protein kinase N1	Kinase	Q16512	PKN1_HUMAN		Kd	5.52	CHEMBL
Serine/threonine-protein kinase 17A	Kinase	Q9UEE5	ST17A_HUMAN		Kd	5.21	CHEMBL
ALK tyrosine kinase receptor	Kinase	Q9UM73	ALK_HUMAN		Kd	5.82	CHEMBL
Ephrin type-A receptor 3	Kinase	P29320	EPHA3_HUMAN		Kd	5.21	CHEMBL
BMP-2-inducible protein kinase	Kinase	Q9NSY1	BMP2K_HUMAN		Kd	6.68	CHEMBL
Dual specificity protein kinase CLK1	Kinase	P49759	CLK1_HUMAN		Kd	5.49	CHEMBL
Dual specificity protein kinase CLK2	Kinase	P49760	CLK2_HUMAN		Kd	6.34	CHEMBL
Cyclin-G-associated kinase	Kinase	O14976	GAK_HUMAN		Kd	7	CHEMBL
Calcium/calmodulin-dependent protein kinase type 1D	Kinase	Q8IU85	KCC1D_HUMAN		Kd	6.92	CHEMBL
Activated CDC42 kinase 1	Kinase	Q07912	ACK1_HUMAN		Kd	5.59	CHEMBL
Ribosomal protein S6 kinase alpha-5	Kinase	O75582	KS6A5_HUMAN		Kd	6.85	CHEMBL
Dual specificity protein kinase CLK4	Kinase	Q9HAZ1	CLK4_HUMAN		Kd	5.77	CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2	Kinase	Q9HBH9	MKNK2_HUMAN		Kd	6.70	CHEMBL
MAP/microtubule affinity-regulating kinase 3	Kinase	P27448	MARK3_HUMAN		Kd	4.83	CHEMBL
Calcium/calmodulin-dependent protein kinase type 1G	Kinase	Q96NX5	KCC1G_HUMAN		Kd	5.66	CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit beta	Kinase	O14920	IKKB_HUMAN		Kd	5.64	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1	Kinase	Q02750	MP2K1_HUMAN		Kd	5.72	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2	Kinase	P36507	MP2K2_HUMAN		Kd	5.40	CHEMBL
BDNF/NT-3 growth factors receptor	Kinase	Q16620	NTRK2_HUMAN		Kd	6.44	CHEMBL
Cyclin-dependent kinase 7	Kinase	P50613	CDK7_HUMAN		Kd	5.48	CHEMBL
Serine/threonine-protein kinase DCLK3	Kinase	Q9C098	DCLK3_HUMAN		Kd	6.59	CHEMBL
Ribosomal protein S6 kinase alpha-6	Kinase	Q9UK32	KS6A6_HUMAN		Kd	6.82	CHEMBL
NUAK family SNF1-like kinase 2	Kinase	Q9H093	NUAK2_HUMAN		Kd	6.49	CHEMBL
Non-receptor tyrosine-protein kinase TYK2	Kinase	P29597	TYK2_HUMAN		Ki	9.30	CHEMBL
Serine/threonine-protein kinase 25	Kinase	O00506	STK25_HUMAN		Kd	5.20	CHEMBL
Serine/threonine-protein kinase RIO1	Kinase	Q9BRS2	RIOK1_HUMAN		Kd	5.60	CHEMBL
NT-3 growth factor receptor	Kinase	Q16288	NTRK3_HUMAN		Kd	6.48	CHEMBL
Casein kinase II subunit alpha	Kinase	P68400	CSK21_HUMAN		Kd	5.38	CHEMBL
Casein kinase II subunit alpha'	Kinase	P19784	CSK22_HUMAN		Kd	5.48	CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Kinase	Q14164	IKKE_HUMAN		Kd	5.92	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 3	Kinase	P46734	MP2K3_HUMAN		Kd	6.33	CHEMBL
Maternal embryonic leucine zipper kinase	Kinase	Q14680	MELK_HUMAN		Kd	5.66	CHEMBL
Serine/threonine-protein kinase 26	Kinase	Q9P289	STK26_HUMAN		Kd	5.51	CHEMBL
Serine/threonine-protein kinase Nek7	Kinase	Q8TDX7	NEK7_HUMAN		Kd	5.31	CHEMBL
Serine/threonine-protein kinase RIO3	Kinase	O14730	RIOK3_HUMAN		Kd	5.70	CHEMBL
SRSF protein kinase 1	Kinase	Q96SB4	SRPK1_HUMAN		Kd	5.68	CHEMBL
Ankyrin repeat and protein kinase domain-containing protein 1	Kinase	Q8NFD2	ANKK1_HUMAN		Kd	6.41	CHEMBL
Myotonin-protein kinase	Kinase	Q09013	DMPK_HUMAN		Kd	5.46	CHEMBL
Leukocyte tyrosine kinase receptor	Kinase	P29376	LTK_HUMAN		Kd	6.36	CHEMBL
Serine/threonine-protein kinase PAK 6	Kinase	Q9NQU5	PAK6_HUMAN		Kd	5.54	CHEMBL
Serine/threonine-protein kinase PAK 7	Kinase	Q9P286	PAK5_HUMAN		Kd	5.89	CHEMBL
Bone morphogenetic protein receptor type-2	Kinase	Q13873	BMPR2_HUMAN		Kd	6.03	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4	Kinase	P45985	MP2K4_HUMAN		Kd	5.74	CHEMBL
Calcium/calmodulin-dependent protein kinase type IV	Kinase	Q16566	KCC4_HUMAN		Kd	6.71	CHEMBL
Mitogen-activated protein kinase kinase kinase 11	Kinase	Q16584	M3K11_HUMAN		Kd	5.72	CHEMBL
Citron Rho-interacting kinase	Kinase	O14578	CTRO_HUMAN		Kd	4.80	CHEMBL
Casein kinase I isoform gamma-1	Kinase	Q9HCP0	KC1G1_HUMAN		Kd	6.07	CHEMBL
Death-associated protein kinase 1	Kinase	P53355	DAPK1_HUMAN		Kd	7.14	CHEMBL
Serine/threonine-protein kinase DCLK1	Kinase	O15075	DCLK1_HUMAN		Kd	7.17	CHEMBL
Serine/threonine-protein kinase DCLK2	Kinase	Q8N568	DCLK2_HUMAN		Kd	6.12	CHEMBL
Serine/threonine-protein kinase PAK 4	Kinase	O96013	PAK4_HUMAN		Kd	5.80	CHEMBL
Serine/threonine-protein kinase PLK3	Kinase	Q9H4B4	PLK3_HUMAN		Kd	6.15	CHEMBL
cGMP-dependent protein kinase 2	Kinase	Q13237	KGP2_HUMAN		Kd	6.16	CHEMBL
Ribosomal protein S6 kinase alpha-1	Kinase	Q15418	KS6A1_HUMAN		Kd	6.92	CHEMBL
Ribosomal protein S6 kinase alpha-4	Kinase	O75676	KS6A4_HUMAN		Kd	6.47	CHEMBL
Casein kinase I isoform alpha	Kinase	P48729	KC1A_HUMAN		Kd	5.74	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2	Kinase	Q12851	M4K2_HUMAN		Kd	5.70	CHEMBL
Serine/threonine-protein kinase TBK1	Kinase	Q9UHD2	TBK1_HUMAN		Kd	5.77	CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Kinase	Q13627	DYR1A_HUMAN		Kd	6.04	CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 2	Kinase	Q92630	DYRK2_HUMAN		Kd	5.43	CHEMBL
Ephrin type-B receptor 6	Kinase	O15197	EPHB6_HUMAN		Kd	5.51	CHEMBL
Serine/threonine-protein kinase/endoribonuclease IRE1	Kinase	O75460	ERN1_HUMAN		Kd	5.60	CHEMBL
Rhodopsin kinase	Kinase	Q15835	RK_HUMAN		Kd	6.14	CHEMBL
G protein-coupled receptor kinase 4	Kinase	P32298	GRK4_HUMAN		Kd	5.21	CHEMBL
G protein-coupled receptor kinase 7	Kinase	Q8WTQ7	GRK7_HUMAN		Kd	6.27	CHEMBL
Homeodomain-interacting protein kinase 2	Kinase	Q9H2X6	HIPK2_HUMAN		Kd	6	CHEMBL
Homeodomain-interacting protein kinase 3	Kinase	Q9H422	HIPK3_HUMAN		Kd	5.92	CHEMBL
Interleukin-1 receptor-associated kinase 1	Kinase	P51617	IRAK1_HUMAN		Kd	6.54	CHEMBL
Mitogen-activated protein kinase kinase kinase 2	Kinase	Q9Y2U5	M3K2_HUMAN		Kd	7.39	CHEMBL
Mitogen-activated protein kinase kinase kinase 3	Kinase	Q99759	M3K3_HUMAN		Kd	6.82	CHEMBL
Microtubule-associated serine/threonine-protein kinase 1	Kinase	Q9Y2H9	MAST1_HUMAN		Kd	6.28	CHEMBL
Serine/threonine-protein kinase OSR1	Kinase	O95747	OXSR1_HUMAN		Kd	5.57	CHEMBL
Serine/threonine-protein kinase RIO2	Kinase	Q9BVS4	RIOK2_HUMAN		Kd	5.92	CHEMBL
SRSF protein kinase 3	Kinase	Q9UPE1	SRPK3_HUMAN		Kd	5.48	CHEMBL
STE20/SPS1-related proline-alanine-rich protein kinase	Kinase	Q9UEW8	STK39_HUMAN		Kd	5.72	CHEMBL
Mitogen-activated protein kinase kinase kinase 7	Kinase	O43318	M3K7_HUMAN		Kd	6.14	CHEMBL
Serine/threonine-protein kinase TAO1	Kinase	Q7L7X3	TAOK1_HUMAN		Kd	5.89	CHEMBL
Serine/threonine-protein kinase TAO3	Kinase	Q9H2K8	TAOK3_HUMAN		Kd	6.23	CHEMBL
Serine/threonine-protein kinase ULK1	Kinase	O75385	ULK1_HUMAN		Kd	6.52	CHEMBL
Serine/threonine-protein kinase ULK2	Kinase	Q8IYT8	ULK2_HUMAN		Kd	6.72	CHEMBL
Serine/threonine-protein kinase ULK3	Kinase	Q6PHR2	ULK3_HUMAN		Kd	5.62	CHEMBL
Mitogen-activated protein kinase kinase kinase 19	Kinase	Q56UN5	M3K19_HUMAN		Kd	6.57	CHEMBL
Homeodomain-interacting protein kinase 1	Kinase	Q86Z02	HIPK1_HUMAN		Kd	5.92	CHEMBL
Mitogen-activated protein kinase kinase kinase 15	Kinase	Q6ZN16	M3K15_HUMAN		Kd	5.96	CHEMBL
Serine/threonine-protein kinase PLK2	Kinase	Q9NYY3	PLK2_HUMAN		Kd	5.82	CHEMBL
Receptor-interacting serine/threonine-protein kinase 4	Kinase	P57078	RIPK4_HUMAN		Kd	5.68	CHEMBL
Uncharacterized serine/threonine-protein kinase SBK3	Kinase	P0C264	SBK3_HUMAN		Kd	5.24	CHEMBL
Mitogen-activated protein kinase kinase kinase 1	Kinase	Q13233	M3K1_HUMAN		Kd	5.38	CHEMBL
Phosphatidylinositol 4-kinase beta	Kinase	Q9UBF8	PI4KB_HUMAN		Kd	5.47	CHEMBL
Serine/threonine-protein kinase SIK3	Kinase	Q9Y2K2	SIK3_HUMAN		Kd	5.89	CHEMBL
Bone morphogenetic protein receptor type-1B	Kinase	O00238	BMR1B_HUMAN		Kd	5.74	CHEMBL
Serine/threonine-protein kinase SBK1	Kinase	Q52WX2	SBK1_HUMAN		Kd	5.89	CHEMBL
Serine/threonine-protein kinase Nek3	Kinase	P51956	NEK3_HUMAN		Kd	5.96	CHEMBL
Peripheral plasma membrane protein CASK	Kinase	O14936	CSKP_HUMAN		Kd	5.82	CHEMBL
Serine/threonine-protein kinase VRK2	Kinase	Q86Y07	VRK2_HUMAN		Kd	5.40	CHEMBL
Serine/threonine-protein kinase TAO2	Kinase	Q9UL54	TAOK2_HUMAN		Kd	6.51	CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2	Kinase	Q5S007	LRRK2_HUMAN		Kd	7.05	CHEMBL
JAK2/JAK1	Kinase	O60674 P23458	JAK2_HUMAN JAK1_HUMAN		IC50	7.51	CHEMBL
JAK3/JAK1	Kinase	P23458 P52333	JAK1_HUMAN JAK3_HUMAN		IC50	7.64	CHEMBL
JAK1/TYK2	Kinase	P23458 P29597	JAK1_HUMAN TYK2_HUMAN		IC50	6.71	CHEMBL
JAK1/JAK2/TYK2	Kinase	O60674 P23458 P29597	JAK2_HUMAN JAK1_HUMAN TYK2_HUMAN		IC50	6.53	CHEMBL
JAK2/TYK2	Kinase	O60674 P29597	JAK2_HUMAN TYK2_HUMAN		IC50	6.09	CHEMBL
Oxysterols receptor LXR-beta	Nuclear other	P55055	NR1H2_HUMAN		Ki	4.35	CHEMBL
Uncharacterized protein FLJ45252	Unclassified	Q6ZSR9	YJ005_HUMAN		Kd	6.71	CHEMBL
STE20-related kinase adapter protein alpha	Kinase	Q7RTN6	STRAA_HUMAN		Kd	5.43	CHEMBL
Serine/threonine-protein kinase 16	Kinase	O75716	STK16_HUMAN		Kd	6.31	CHEMBL
MAP kinase-activated protein kinase 5	Kinase	Q8IW41	MAPK5_HUMAN		Kd	5.51	CHEMBL
Tyrosine-protein kinase JAK3	Kinase	P52333	JAK3_HUMAN		Kd	8.70	CHEMBL
Tyrosine-protein kinase JAK2	Kinase		JAK2_MOUSE		EC50	6.73	CHEMBL
Serine/threonine-protein kinase PknB	Kinase		PKNB_MYCTU		Kd	5.38	CHEMBL

External reference:

ID	Source
4031235	VUID
N0000184017	NUI
D09959	KEGG_DRUG
4031235	VANDF
C2931926	UMLSCUI
CHEBI:66919	CHEBI
RXT	PDB_CHEM_ID
CHEMBL1789941	ChEMBL_ID
CHEMBL1795071	ChEMBL_ID
DB08877	DRUGBANK_ID
C540383	MESH_SUPPLEMENTAL_RECORD_UI
5688	IUPHAR_LIGAND_ID
9287	INN_ID
1092939-17-7	SECONDARY_CAS_RN
82S8X8XX8H	UNII
25126798	PUBCHEM_CID
1193325	RXNORM
186162	MMSL
28206	MMSL
39982	MMSL
d07812	MMSL
014040	NDDF
014041	NDDF
702806008	SNOMEDCT_US
703779004	SNOMEDCT_US
734494005	SNOMEDCT_US
82S8X8XX8H	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
JAKAFI	HUMAN PRESCRIPTION DRUG LABEL	1	50881-005	TABLET	5 mg	ORAL	NDA	30 sections
OPZELURA	HUMAN PRESCRIPTION DRUG LABEL	1	50881-007	CREAM	15 mg	TOPICAL	NDA	28 sections
OPZELURA	HUMAN PRESCRIPTION DRUG LABEL	1	50881-007	CREAM	15 mg	TOPICAL	NDA	28 sections
JAKAFI	HUMAN PRESCRIPTION DRUG LABEL	1	50881-010	TABLET	10 mg	ORAL	NDA	30 sections
JAKAFI XR	HUMAN PRESCRIPTION DRUG LABEL	1	50881-011	TABLET, EXTENDED RELEASE	11 mg	ORAL	NDA	30 sections
JAKAFI	HUMAN PRESCRIPTION DRUG LABEL	1	50881-015	TABLET	15 mg	ORAL	NDA	30 sections
JAKAFI	HUMAN PRESCRIPTION DRUG LABEL	1	50881-020	TABLET	20 mg	ORAL	NDA	30 sections
JAKAFI XR	HUMAN PRESCRIPTION DRUG LABEL	1	50881-022	TABLET, EXTENDED RELEASE	22 mg	ORAL	NDA	30 sections
JAKAFI	HUMAN PRESCRIPTION DRUG LABEL	1	50881-025	TABLET	25 mg	ORAL	NDA	30 sections
JAKAFI XR	HUMAN PRESCRIPTION DRUG LABEL	1	50881-033	TABLET, EXTENDED RELEASE	33 mg	ORAL	NDA	30 sections
JAKAFI XR	HUMAN PRESCRIPTION DRUG LABEL	1	50881-044	TABLET, EXTENDED RELEASE	44 mg	ORAL	NDA	30 sections
JAKAFI XR	HUMAN PRESCRIPTION DRUG LABEL	1	50881-055	TABLET, EXTENDED RELEASE	55 mg	ORAL	NDA	30 sections

Ask DrugCentral

ruxolitinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: